We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+13.94%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$284M
AUM Growth
+$26.8M
Cap. Flow
+$26.8M
Cap. Flow %
9.46%
Top 10 Hldgs %
45.99%
Holding
71
New
15
Increased
14
Reduced
11
Closed
6

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.32M
2
SHPG
Shire pic
SHPG
+$4.62M
3
EXEL icon
Exelixis
EXEL
+$4.15M
4
TSRO
TESARO, Inc.
TSRO
+$4.15M
5
STML
Stemline Therapeutics, Inc.
STML
+$4.15M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$5.75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$4.98M
3
CALA
Calithera Biosciences, Inc
CALA
+$2.95M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$2.4M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
2 Miscellaneous 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$32.7B
$20.7M 7.3%
65,008
-6,500
-9% -$2.09M
CELG
2
DELISTED
Celgene Corp
CELG
$19.8M 6.99%
190,022
+9,500
+5% +$1.07M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$83.1B
$15.4M 5.41%
40,830
– –
NKTR icon
4
Nektar Therapeutics
NKTR
$2.55B
$12.6M 4.44%
+14,067
New +$8.32M
EXEL icon
5
Exelixis
EXEL
$13.7B
$12.5M 4.4%
410,334
+156,000
+61% +$4.15M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$139B
$11.3M 3.99%
75,422
-13,300
-15% -$1.97M
ADMS
7
DELISTED
Adamas Pharmaceuticals
ADMS
$10.7M 3.76%
315,000
-75,000
-19% -$2.09M
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$5.13B
$10M 3.54%
333,773
+93,000
+39% +$2.97M
GILD icon
9
Gilead Sciences
GILD
$185B
$8.8M 3.1%
122,784
– –
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$8.66M 3.05%
72,441
-19,700
-21% -$2.4M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$8.48M 2.99%
51,496
+34,500
+203% +$3.34M
ENTL
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$8.32M 2.94%
341,468
– –
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$7.69M 2.71%
492,930
+310,000
+169% +$4.15M
INCY icon
14
Incyte
INCY
$25.9B
$6.91M 2.44%
72,975
-16,000
-18% -$1.67M
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$6.41M 2.26%
77,300
+42,300
+121% +$4.15M
AMGN icon
16
Amgen
AMGN
$236B
$6.28M 2.21%
36,104
– –
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$6.11M 2.15%
477,500
+230,000
+93% +$2.62M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$12.6B
$6.1M 2.15%
68,384
– –
HALO icon
19
Halozyme
HALO
$12.1B
$5.72M 2.02%
282,633
– –
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$5.17M 1.82%
76,000
+20,000
+36% +$1.4M
SHPG
21
DELISTED
Shire pic
SHPG
$4.84M 1.71%
+31,200
New +$4.62M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$31.6B
$4.67M 1.65%
36,800
-4,500
-11% -$565K
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.54M 1.6%
253,500
+51,500
+25% +$1.07M
LGND icon
24
Ligand Pharmaceuticals
LGND
$5.67B
$3.97M 1.4%
46,487
– –
BLUE
25
DELISTED
bluebird bio
BLUE
$3.56M 1.26%
1,544
– –
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2017 Portfolio in Review

As of Q4 2017, International Biotechnology Trust held 71 positions worth $284M, up 10% from $257M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

International Biotechnology Trust deployed $26.8M of net new capital in Q4 2017, opening 15 new positions and adding to 14 existing holdings. Its largest new stake was Nektar Therapeutics: 14,067 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $4.98M trimmed.

  • International Biotechnology Trust's largest Q4 2017 buy was Nektar Therapeutics: 14,067 shares worth $12.6M.
  • International Biotechnology Trust added most to Exelixis in Q4 2017, an estimated $4.15M increase.
  • International Biotechnology Trust's biggest Q4 2017 reduction was Sarepta Therapeutics, cutting an estimated $4.98M.
  • International Biotechnology Trust fully exited Acceleron Pharma in Q4 2017, selling an estimated $5.75M.
  • International Biotechnology Trust's ten largest holdings make up 46% of its $284M portfolio in Q4 2017.
  • International Biotechnology Trust opened 15 new positions and closed 6 in Q4 2017.
  • International Biotechnology Trust's portfolio value rose 10% quarter-over-quarter to $284M.

Based on International Biotechnology Trust's 13F filing for Q4 2017, filed 2 Mar 2018.